6-Bromospiro[benzo[e][1,3]oxazine-2,4'-piperidin]-4(3H)-one

Catalog No.: 
ACCJLP243
CAS No.: 
691868-45-8
Molecular Formula: 
C12H13BrN2O2
Molecular Weight: 
297.15
6-Bromospiro[benzo[e][1,3]oxazine-2,4'-piperidin]-4(3H)-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$100.00InquiryInquiry
1g95%$319.00InquiryInquiry
5g95%$1579.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name6-Bromospiro[benzo[e][1,3]oxazine-2,4'-piperidin]-4(3H)-one
IUPAC Name6-bromospiro[benzo[e][1,3]oxazine-2,4'-piperidin]-4(3H)-one
MDL No.MFCD13195396
Molecular FormulaC12H13BrN2O2
Molecular Weight297.15
SMILESO=C1NC2(CCNCC2)OC3=CC=C(Br)C=C13
InChI KeySBEOZVCCSJKAHX-UHFFFAOYSA-N
Synonym6-BroMospiro[benzo[e][1,3]oxazine-2,4'-piperidin]-4(3H)-one;6-bromospiro[3H-1,3-benzoxazine-2,4'-piperidine]-4-one;Spiro[2H-1,3-benzoxazine-2,4'-piperidin]-4(3H)-one, 6-bromo-
CAS No.691868-45-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACCJLP243 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACCJLP243 route product structure diagram
    ACCJLP243691868-45-8
Inquiry

2. ACCJLP243 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACCJLP243 route product structure diagram
    ACCJLP243691868-45-8
Inquiry

3. ACCJLP243 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACCJLP243 route product structure diagram
    ACCJLP243691868-45-8
Inquiry

Comments (0)